EXAS

Exact Sciences offers a portfolio of cancer screening and diagnostic tests that cover early detection through post-treatment monitoring. The company provides Cologuard, a stool-based DNA test for colorectal cancer screening, along with Cologuard Plus, a newer version designed to improve sensitivity and reduce false positives. In oncology, Exact Sciences delivers the Oncotype DX Breast Recurrence Score test, which evaluates gene expression in tumor tissue to estimate recurrence risk and guide treatment decisions. It also offers the OncoExTra test, which conducts comprehensive genomic profiling of advanced solid tumors using both DNA and RNA analysis to support therapy selection. For post-treatment monitoring, Exact Sciences provides the Oncodetect molecular residual disease test that identifies tumor-specific circulating DNA in blood to detect minimal residual disease and potential recurrence. The company further supports clinical workflows through its laboratory network and a digital platform that helps clinicians manage test orders, results, and patient information.